One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
La Jolla Pharmaceutical Company logo
La Jolla Pharmaceutical Company LJPC
report update icon

Quarterly report 2022-Q2
added 05-23-2026

La Jolla Pharmaceutical Company Financial Statements 2021-2009 | LJPC

Annual Financial Statements La Jolla Pharmaceutical Company

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

127 M 167 M 186 M 154 M 727 M 335 M 277 M 233 M 13 M 1.02 B - - -

Shares

27.4 M 27.3 M 27.1 M 25.4 M 21.2 M 17.2 M 15.7 M 10.7 M 1.54 M 204 M 369 K 947 K -

Historical Prices

4.63 6.12 6.85 6.04 34.3 19.4 17.7 21.8 8.45 5 - - -

Net Income

19.7 M -39.4 M -117 M -199 M -115 M -78.2 M -41.9 M -21.3 M -17.9 M -7.74 M -11.5 M -3.76 M -

Revenue

75.7 M 33.4 M 23.1 M 10.1 M - 616 K 1.06 M - - - - - -

Cost of Revenue

- 7.82 M 2.39 M 1.64 M - - - - - - - - -

Gross Profit

- 25.6 M 20.7 M 8.41 M - - - - - - - - -

Operating Income

21.8 M -35.8 M -110 M -194 M -115 M -78.4 M -42 M -21.3 M -17.9 M -10.7 M -2.27 M -3.93 M -

Interest Expense

733 K -46 K -6.71 M 7.3 M - - 57 K 27 K 6 K 4 K 234 K -1 K -

EBITDA

21.9 M -33.6 M -105 M -190 M -114 M -77.6 M -41.6 M -21.3 M -17.9 M -10.7 M -2.27 M -3.93 M -

Operating Expenses

- 61.4 M 130 M 202 M 115 M 79 M 43 M 21.3 M 17.9 M 10.7 M 2.27 M - -

General and Administrative Expenses

35.4 M 38.4 M 45.1 M 85.2 M 30.9 M 16.7 M 13.9 M 11.4 M 13.6 M 9.39 M 2.1 M 3.92 M -

All numbers in USD currency

Quarterly Income Statement La Jolla Pharmaceutical Company

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - 25.3 M 26.2 M 26.8 M 27.5 M 27.5 M 27.4 M 27.4 M 27.4 M 27.3 M 27.2 M 27.2 M 27.1 M 27.1 M 27 M 26.3 M 26.2 M 26.2 M 22.7 M 22.2 M 22.1 M 22.1 M 18.4 M 17.3 M 17.2 M 17.2 M 17.2 M 17.2 M 14.9 M 15.3 M 15.2 M 15.2 M 13.6 M 6.84 M 5.54 M 4.4 M 41.4 M 27.5 M 17.5 M 285 K 13.3 M 11.6 M 2.09 M 875 K 53.3 M 12.4 M 947 K

Net Income

- - 2.46 M 2 K - -2.26 M 3.73 M 14.4 M - -11.8 M -15.6 M -8.59 M - -29.2 M -30.4 M -31.7 M - -50.7 M -52.8 M -50.5 M -38.5 M -26.3 M -26.7 M -23.2 M -24.9 M -53.3 M -32 M -16.5 M -11.8 M -30.1 M -19.6 M -8.96 M -6.85 M -5.05 M -4.28 M -5.13 M - -4.17 M -3.16 M -4.2 M - -2.22 M -7.7 M 5.28 M - 3.57 M 4.71 M -6.51 M

Revenue

- - 10.5 M 10.4 M - 13.3 M 16.1 M 34.1 M - 9.07 M 5.8 M 7.59 M - 5.71 M 5.7 M 4.4 M - 3.47 M 1.59 M 809 K - - - - 85 K 44 K 253 K 234 K 410 K 647 K - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - 2.49 M 808 K 716 K - 554 K 551 K 500 K - 256 K 129 K 58 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - -1.07 M -2.05 M - 525 K 3.79 M 17.5 M - -9.53 M -12.5 M -10.5 M - -26.8 M -28.2 M -29.7 M - -48.4 M -51.6 M -50.7 M -38.8 M -26.5 M -26.8 M -23.3 M -24.9 M -21.3 M -15.6 M -16.5 M -11.9 M -10.5 M -10.7 M -8.97 M -6.86 M -5.06 M -4.29 M -5.13 M - -4.17 M -3.16 M -4.2 M - -3.45 M -3.21 M -671 K - -423 K -904 K -478 K

Interest Expense

- - -489 K 543 K - -25 K 80 K -450 K - 281 K -693 K 1.87 M - -2.36 M -2.2 M -2.02 M - -2.38 M -1.21 M 166 K - 195 K 101 K 28 K - 46 K 51 K 32 K - 13 K 8 K 11 K - 9 K 2 K 2 K - 1 K 1 K 1 K - -1 K 1 K 1 K - 234 K 236 K -2 K

EBITDA

- - -1.02 M -2.02 M - 609 K 3.85 M 17.5 M - -7.37 M -10.7 M -9.4 M - -23.4 M -26 M -28.5 M - -45.1 M -49.5 M -49.7 M -38.8 M -25.6 M -26.2 M -23 M -24.9 M -20.8 M -15.3 M -16.4 M -11.9 M -10.4 M -10.6 M -8.96 M -6.86 M -5.05 M -4.28 M -5.13 M - -4.17 M -3.16 M -4.2 M - -3.45 M -3.21 M -671 K - -423 K -904 K -478 K

General and Administrative Expenses

- - 9.76 M 10.3 M - 8.63 M 9 M 8.76 M - 12.5 M 8.68 M 8.15 M - 10.8 M 11.3 M 12.3 M - 21.1 M 22.2 M 23 M - 7.39 M 6.02 M 5.5 M - 4.35 M 3.47 M 4.05 M - 3.35 M 3.97 M 3.8 M - 2.44 M 2.69 M 3.13 M - 3.22 M 2.46 M 3.55 M - 2.97 M 2.88 M 637 K - 423 K 727 K 478 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements La Jolla Pharmaceutical Company LJPC
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting La Jolla Pharmaceutical Company plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Replimune Group Replimune Group
REPL
$ 19.07 -0.83 % $ 1.77 B usaUSA
NextCure NextCure
NXTC
$ 6.62 -2.43 % $ 35.2 M usaUSA
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 1.95 -7.82 % $ 217 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 0.87 -33.79 % $ 45.7 M usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 553.08 -1.08 % $ 24.5 B usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
$ 7.0 -2.1 % $ 609 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 115.19 -3.52 % $ 9.73 B usaUSA
Oragenics Oragenics
OGEN
$ 0.16 -6.16 % $ 345 K usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
$ 2.2 -5.98 % $ 286 M usaUSA
Passage Bio Passage Bio
PASG
$ 3.94 9.14 % $ 12.6 M usaUSA
Vaxcyte Vaxcyte
PCVX
$ 55.37 -5.12 % $ 7.54 B usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
$ 16.11 1.26 % $ 2.76 B usaUSA
Precigen Precigen
PGEN
$ 4.21 1.08 % $ 1.32 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 6.94 -0.57 % $ 956 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
$ 0.66 -7.55 % $ 3.95 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
$ 300.01 -3.5 % $ 6.75 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.22 -1.08 % $ 248 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.02 -2.38 % $ 107 M niderlandNiderland
Ocular Therapeutix Ocular Therapeutix
OCUL
$ 5.57 -5.03 % $ 1.04 B usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 1.58 -9.2 % $ 400 M usaUSA
Outlook Therapeutics Outlook Therapeutics
OTLK
$ 0.39 -2.79 % $ 13.6 M usaUSA
uniQure N.V. uniQure N.V.
QURE
$ 19.32 -4.5 % $ 1.11 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
$ 16.46 -4.41 % $ 1.62 B usaUSA
Rafael Holdings Rafael Holdings
RFL
$ 0.94 5.89 % $ 48.3 M usaUSA
REGENXBIO REGENXBIO
RGNX
$ 7.16 -0.35 % $ 369 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 40.05 -2.78 % $ 720 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.27 -8.27 % $ 49.8 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 514.68 -1.15 % $ 132 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
$ 13.67 -8.01 % $ 1.49 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Rezolute Rezolute
RZLT
$ 3.92 -6.69 % $ 407 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 0.63 -7.05 % $ 67.2 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Seer Seer
SEER
$ 1.34 -3.25 % $ 74.5 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Summit Therapeutics Summit Therapeutics
SMMT
$ 9.94 -6.01 % $ 7.43 B britainBritain
Shattuck Labs Shattuck Labs
STTK
$ 4.49 -1.43 % $ 312 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 19.81 0.08 % $ 2.81 B britainBritain